Intestinal microbiota are implicated in the regulation of multiple host metabolic pathways that contribute to phenotypes such as obesity and insulin resistance (9). Our group has recently described a mechanistic link between intestinal microbedependent generation of trimethylamine-N-oxide (TMAO) and increased risk for future cardiovascular events (death, myocardial infarction, and stroke) by a pathway involving dietary nutrients such as phosphatidylcholine, choline, and carnitine (10-12).
In chronic systolic HF, the relationship between the intestinal microbiota-generated metabolite TMAO BNP, high-sensitivity C-reactive protein (hsCRP), fasting lipid panel, uric acid, and serum creatinine were measured using the Architect ci8200 platform (Abbott Laboratories, Abbott Park, Illinois). Serum arylesterase activity was measured in the same platform as previously described (13) 2.5 to 13.2; p < 0.01) compared with both low BNP and TMAO levels ( Figure 3 ).
DISCUSSION
The key finding to our study is the strong prognostic value of plasma TMAO levels in patients with stable HF incremental to traditional risk factors, cardiorenal indexes (BNP and eGFR), and markers of systemic inflammation (hsCRP). It is intriguing that in the setting of elevated natriuretic peptide levels, which often represent significant myocardial disease progression, a relatively low fasting TMAO level was associated with far lower mortality risk than that seen with elevated levels of both markers. These observations in a large population of HF patients further 
